| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | TMC278 | |
| 3 | Generic Name | rilpivirine | |
| 4 | Indication | HIV | |
| 5 | Mechanism | NNRTI | |
| 6 | Safety | Was previously suspended following QT prolongation at high doses. | |
| 7 | Clinical Trials | ||
| 8 | Phase III "ECHO" head-to-head versus Sustiva | ||
| 9 | 25mg vs EFV 600mg with fixed Truvada background. | ||
| 10 | n=680 global study, 48-week primary endpoint. | ||
| 11 | |||
| 12 | Phase III "THRIVE" head-to-head versus Sustiva | ||
| 13 | 25mg vs EFV 600mg with investigator-selected backrgound therapy. | ||
| 14 | n=680 global study, 48-week primary endpoint. |